Conferences - Results from #160

ASTRO 2024: Bladder Cancer - The Dawn or Era of More Personalized Radiotherapy September 29, 2024

ASTRO 2024: Integrating Novel Therapeutics with Trimodal Therapy (TMT) September 29, 2024

ASTRO 2024: Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial September 29, 2024

ASTRO 2024: Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial September 29, 2024

ASTRO 2024: The Space-Time Continuum in Metastatic Castration-Sensitive Prostate Cancer: The Final Frontier? September 29, 2024

ASTRO 2024: Bladder Preservation - A Modern Choice for Patients September 29, 2024

ASTRO 2024: Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP) September 29, 2024

ASTRO 2024: Precision in Practice: Optimizing Prostate Radiation with MRI-Defined Microboost September 29, 2024

ASTRO 2024: A Prospective Pilot Study Investigating 18F rhPSMA-7.3 PET/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Prostatectomy September 29, 2024

ASTRO 2024: SABR for Primary RCC – Is It Ready for Primetime? September 29, 2024

ASTRO 2024: Radiotherapy of the Primary Tumor and All Metastatic Lesions in Oligometastatic Prostate Cancer: 5-Year Results of Prolong Study September 29, 2024

ASTRO 2024: Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients with Localized Prostate Cancer: Toxicity and Quality-of Life Results from a Prospective Trial September 29, 2024

ASTRO 2024: Impact of Prior Local Therapy on Treatment Response and Survival of Men with Metastatic Castrate Resistant Prostate Cancer: A Pooled Analysis of COU-AA-302 and ACIS Trials September 29, 2024

IBCN 2024: Mechanisms of Resistance to Antibody Drug Conjugates September 21, 2024

IBCN 2024: Systematic Evaluation of Differentially Expressed Genes Associated with Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer September 21, 2024

IBCN 2024: Quantifying Intra-tumoral Molecular Subtype Heterogeneity in MIBC from Histological Slides using a deep learning approach in the VESPER Trial September 21, 2024

IBCN 2024: Oncolytic Virotherapy Expressing a Novel TLR Agonist and IL-15 for the Treatment of NMIBC September 21, 2024

IBCN 2024: Spatial Proteomics and Transcriptomics Reveal an Altered Immune Cell Landscape in Bladder Cancer Patients Unresponsive to BCG Treatment September 21, 2024

IBCN 2024: Molecular Subtypes and Outcomes in the VESPER Trial September 21, 2024

IBCN 2024: Molecular Subtyping in 2024: The LUMBER-NAC Trial September 21, 2024

Page 9 of 594